An independent guide to cash-pay care. Every price is dated and sourced.

How we check

Medical weight loss in Chicago

For many Chicagoans, medical weight loss means a prescriber, some lab work and a GLP-1 such as Zepbound or Wegovy, bought with cash because Illinois Medicaid does not cover these drugs for obesity [1]. On Oct 17, 2026, Lilly's lowest Zepbound price was $299 a month and Novo's Wegovy pen was $349 [2] [3].

Medical review: pending. A licensed clinician has not yet reviewed this page.

Medical weight loss is weight treatment run by a licensed prescriber that may use FDA-approved drugs, lab checks and changes to food and activity.

Cook County adults with obesity
31.0% (2023) [4]
Cook County adults with diabetes
11.8% [4]
Illinois Medicaid, obesity GLP-1s
Not covered [1]
Cheapest brand option
$149 a month, Wegovy tablet 1.5 mg [3]
Fee splitting
Barred by 225 ILCS 60/22.2 [18]

Cook County numbers behind the demand

About 2,731,585 people lived in Chicago on July 1, 2025 [5]. Across Cook County, CDC PLACES estimates 31.0% of adults had obesity in 2023 and 11.8% had a diabetes diagnosis [4]. Those are the groups weight drugs are labeled for: Zepbound is approved for adults with obesity, or with overweight plus a weight-related condition [6].

Coverage is the sticking point. Lilly, quoting an IFEBP survey, says roughly half of Americans with job-based insurance have no benefit for obesity drugs [7]. New to all this? Start with the weight loss guide.

That listing is paid placement. We label it, and it is not a recommendation. See how we make money.

Three routes to a Chicago prescription

  • Your own primary care doctor or an endocrinologist. Often cheapest when your plan pays for visits, even if the drug is still self-pay.
  • A storefront weight clinic. Fees are rarely posted. Ask whether the monthly charge buys visits, labs, the drug, or only the prescription.
  • Telehealth. A prescriber with an Illinois license sees you by video or form and sends the order to a pharmacy. Compare programs on online GLP-1 programs.

Northwestern Medicine, Rush University System for Health and UChicago Medicine are the city's big academic systems. None of them posts a weight management price list that we found, so call primary care or endocrinology and ask. Questions to bring are in our clinic finder checklist. Drug-specific local pages: tirzepatide in Chicago and semaglutide in Chicago.

The drug's price, before a clinic adds anything

Wegovy tablets start at $149 for 1.5 mg, then $199 at 4 mg and $299 at 9 or 25 mg; Wegovy pens are $349 for any dose from 0.25 to 2.4 mg [3]. Zepbound is $299 to $449 at LillyDirect, more if a refill runs late [2], against a $1,087 list price [9]. Foundayo, Lilly's tablet, is $149 to $299 [8]. A Chicago clinic quoting one flat monthly figure is either folding its fee into one of these prices or selling a compounded drug. Ask which, and read compounded tirzepatide if it is the second. Full detail: GLP-1 cost guide.

Illinois coverage: Medicaid, Medicare and job-based plans

KFF's January 2026 list of 13 states paying for obesity GLP-1s through Medicaid leaves Illinois out [1]. Members with type 2 diabetes are a separate case, since Ozempic and Mounjaro are diabetes drugs. For Chicagoans on Part D, the temporary Medicare GLP-1 Bridge runs July 1, 2026 to December 31, 2027 at a $50 monthly copay for those who qualify [10] [11]; see our Medicare GLP-1 page. A worker whose plan already covers Zepbound may pay as little as $25 with Lilly's savings card [12].

Checking a clinic before you pay

  1. Search the prescriber in the Illinois Department of Financial and Professional Regulation license lookup [13].
  2. Know the state rule: the Illinois Medical Practice Act bars licensees from sharing fees with others in return for referrals, apart from listed arrangements [18]. Referral bonuses are a warning sign.
  3. Look the company up in our FDA warning letter tracker. In a single wave announced March 3, 2026, FDA warned 30 telehealth firms [14].
  4. Ask for the pharmacy's name and whether the product is brand or compounded.
  5. Get refund and cancellation terms in writing before the first charge.

Neighboring guides: Indianapolis, Detroit, Minneapolis and St. Louis, where Missouri's Medicaid rules differ from Illinois.

Safety points from the labels

Elsewhere in the Upper Midwest, our Minneapolis weight loss guide covers Minnesota's Medicaid and board rules.

When to stop and call

Because tirzepatide and semaglutide caused thyroid C-cell tumors in rodents, Zepbound and Wegovy carry a boxed warning, and no one with medullary thyroid carcinoma or MEN 2 in their personal or family history should use them [15] [16]. Severe stomach pain that persists may be pancreatitis; stop and get care. Lows are likelier alongside insulin or a sulfonylurea [15]. Wegovy should stop at least 2 months before a planned pregnancy [16]. Swelling of the face or throat, or trouble breathing: call 911.

Questions people ask

What does medical weight loss cost in Chicago?

The medicine alone ran $149 to $449 a month at maker cash prices on Oct 17, 2026: the Wegovy tablet from $149, the Wegovy pen $349 and Zepbound $299 to $449 [3] [2]. Chicago clinics add their own visit and lab fees.

Does Illinois Medicaid pay for Wegovy or Zepbound to treat obesity?

No. Illinois was not among the 13 state Medicaid programs KFF found covering obesity GLP-1s in January 2026 [1].

What share of Cook County adults have obesity?

31.0% in 2023, by CDC PLACES estimates, with 11.8% reporting diagnosed diabetes [4].

Can I be prescribed a GLP-1 online in Illinois?

Yes, when the prescriber holds an Illinois license, which IDFPR's lookup will show [13]. Then compare the program's drug price with the maker's own, such as $349 a month for the Wegovy pen [3].

Can Chicago seniors use Medicare for weight loss drugs?

Those who qualify can use the Medicare GLP-1 Bridge for Wegovy, Foundayo or a Zepbound KwikPen at $50 a month between July 1, 2026 and December 31, 2027 [10] [11].

Can an Illinois clinic pay doctors for referrals?

Generally no. 225 ILCS 60/22.2 bars licensees from splitting fees with others in return for referrals, apart from specified arrangements [18].

What did the main Zepbound trial show?

In SURMOUNT-1, adults without diabetes on 15 mg averaged 20.9% weight loss at 72 weeks, versus 3.1% on placebo [17]. Individuals varied widely.

Sources

18 cited
  1. Medicaid Coverage of and Spending on GLP-1s. KFF, Jan 16, 2026.
  2. Zepbound self-pay pricing. Eli Lilly and Company (LillyDirect), accessed 2026-10-17.
  3. Wegovy self-pay offer. Novo Nordisk (NovoCare Pharmacy), accessed 2026-10-17.
  4. PLACES county data: Cook County, IL. CDC PLACES (2025 release, BRFSS 2023), 2023 data, 2025 release.
  5. QuickFacts: Chicago city, Illinois. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
  6. Zepbound label. DailyMed, NLM, Aug 2026.
  7. Foundayo now available. Eli Lilly and Company, Apr 9, 2026.
  8. Foundayo self-pay pricing. Eli Lilly and Company (LillyDirect), accessed 2026-10-17.
  9. TrumpRx.gov. TrumpRx.gov (US government), accessed 2026-10-17.
  10. Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
  11. Weight loss drugs coverage. Medicare.gov (CMS), accessed 2026-10-17.
  12. Zepbound coverage and savings. Eli Lilly and Company, accessed 2026-10-17.
  13. Physicians: licensing and discipline. Illinois Department of Financial and Professional Regulation, accessed 2026-10-17.
  14. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. US Food and Drug Administration, Mar 3, 2026.
  15. Zepbound prescribing information. US FDA (accessdata.fda.gov), Apr 2026.
  16. Wegovy label. DailyMed, NLM, Jun 2026.
  17. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine (PubMed), Jun 4, 2022.
  18. Medical Practice Act, 225 ILCS 60/22.2 (fee splitting). Illinois General Assembly, accessed 2026-10-17.

This page is general information, not medical advice. Talk with a licensed clinician about your own care.

Compare online GLP-1 programs